Yelena Janjigian/LinkedIn
Jun 1, 2025, 04:49
Results from Event-free survival (EFS) in Matterhorn – Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center shared a post on LinkedIn:
“Plenary session alert: MSK gastrointestinal oncologist Dr. Yelena Janjigian.
Will share results from “Event-free survival (EFS) in MATTERHORN: A randomized, phase 3 study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel chemotherapy (FLOT) in resectable gastric/gastroesophageal junction cancer (GC/GEJC)” TODAY at the American Society of Clinical Oncology (ASCO) Annual Meeting.
Date: 6/1 at 3:13pm CT.”
Memorial Sloan Kettering announced that Dr. Yelena Janjigian will present results from the MATTERHORN phase 3 trial during a plenary session at ASCO. The study evaluates event-free survival for durvalumab in combination with FLOT chemotherapy in patients with resectable gastric or gastroesophageal junction cancer.
More posts featuring Memorial Sloan Kettering Cancer Center.
American Society of Clinical Oncology
ASCO
cancer
Durvalumab
fight against cancer
fluorouracil
gastroesophageal junction cancer
Global fight against cancer
leucovorin
MATTERHORN
Memorial Sloan Kettering Cancer Center
MSKCC
OncoDaily
Oncology
oxaliplatin
oxaliplatin and docetaxel chemotherapy
Yelena Janjigian
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 26, 2025, 14:50
Jun 26, 2025, 14:20
Jun 26, 2025, 13:31